Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

Launched by UNIVERSITY OF COLORADO, DENVER · May 7, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring how certain health interventions can help women aged 45-55 who are going through the menopausal transition. As women enter menopause, they may face an increased risk of heart and metabolic issues, along with uncomfortable symptoms like hot flashes. The researchers aim to see if evidence-based strategies can reduce inflammation, improve heart health, and lessen these bothersome symptoms, ultimately enhancing the quality of life for women during this stage.

To participate in the study, women need to be between 45 and 55 years old and in the late stages of menopause, which means they haven't had a period for about two months but less than a year. They should not be using hormone therapy or contraception, must have a uterus and at least one ovary, and have access to a smartphone and reliable internet for telehealth appointments. Participants can expect to engage in health interventions and provide feedback through electronic surveys. It’s important to note that the trial is not yet recruiting participants, so there’s no immediate need to apply.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • aged 45-55
• • In the late menopausal transition, defined as 60 days of amenorrhea but less than 365 days of amenorrhea18
• • No current use of hormone therapy or hormonal contraception
• • Presence of a uterus and at least one ovary in order to track menstrual patterns
• • Have a smartphone and broadband access adequate to accept telehealth appointments
• Exclusion Criteria:
• • Lack of broadband access (activity and survey data will be collected electronically whenever possible and some visits will be via telehealth)
• • Lack of regular menstrual periods in mid-reproductive life (ages 25-38) when not on hormones or not pregnant.
• • Pregnancy or actively trying to get pregnant
• • Inability to adhere to study protocol schedule
• • Untreated alcoholism
• • Un- Diagnosed abnormal uterine bleeding
• • Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (MEN 2) for participants with a BMI\> 30 kg/m2.